We are pleased to inform you that the Company ahs received letter from National Stock Exchange of India Limited dated 23-Oct-2026 stating that the equity shares of the Company shall be listed and admitted to dealings on the Exchange (Capital Market segment) w.e.f. 27-Oct-2026 pursuant to migration from SME platform of BSE Limited.

EUDARTHAII PHAR]IA IIIDUSIRIES TTD Head Otfice : 301 . ALrra B p ex. Premium Retail Premises 7,S.VFoad Borival (West), Ivurnba 400092. E-mail : comp ance@sudarshanpharma.com Website: !4ryr'w.sLrdarshanpharma.com BoardLine:+91-22-42221111r43331111r42221116{100line).ClN:151496[,1H2008P1CT84997 sP tL/ cs /sE/ 2026-27 / 69 . Date: 23'd October 2026 The Listing Department BSE Limited BSE Scrip Coder 543828 Phiroze Jeejeebhoy Towers, BSE Trading Symbo : SUDARSHAN Dalal Street, Mumbai - 400 001 S N: NE00TV01023 Sub: Discloiure pursuant to Regulation 30 of the SEgl (Listing Obligations and Oisclosure Requirements) Regulations, 2015 Ref: lJpdates on migration {rom SME Platform of BSE to Capital Market Segment (Main Board) of National Stock Exchange of lndia Limited of Sudarshan Pharma lndustries Limited - Company Letter bearing ref. no. SPIL/CS/SE/2026-2027 /2O daled 2l'r May 2026 PLlrsuant to Regulation 30 of SEBl (Llstine Ob igation and D sc osure Requirements) Regu ations, 2015 and in continuation of the Company's letter bearing ref. no- SPIL/CS/sE /2026 2A27 /20 daled 21\1May, 2026, we are peased to inform you that the Company has received letter from NatlonaL Stock Exchange of ndia Lmited bearing rei. no. NSE/L ST/78 dated 23'd October,2026, statlng that the eq! ty shares of the Company shall be llsted and admitted to deallngs on the Exchange (Capita Market Segment) w.e.f. October 27, 2026 pursuant to miBration from SME P atform of BSE. You are requested to take the saine on record For, Sudarshan Pharma lndustries Limited Company Secretary & Complla Encl: NSE Letter dated 23'dOctober 'ri l, Hegd. Otl. : 301, Aura Biplex, Above Kalyan Jewellers, S.V Road, Borivali West), l\4umbai - 400092 Ref: NSE/LIST/78 October 23, 2026 The Company Secretary Sudarshan Pharma Industries Limited 301,3rd Floor, Aura Biplex, Above Kalyan Jewellers S. V. Road, Borivali (West), Mumbai City, Maharashtra 400092 Kind Attn: Mr. Nirav Kishor Shah Dear Sir, Re.: Listing of Equity Shares of Sudarshan Pharma Industries Limited pursuant to Migration from SME Platform of BSE to Capital Market Segment (Main Board) of National Stock Exchange of India Limited. This is with reference to your application for listing and trading in equity shares of the Company on Capital Market Segment (Main Board) of National Stock Exchange of India Limited. We are pleased to inform you that the equity shares of the Company shall be listed and admitted to dealings on the Exchange (Capital Market Segment) w.e.f. October 27, 2026 pursuant to Migration from SME Platform of BSE as per the details given below: Sr. No. of Mkt. Distinctive Description of Securities Symbol Series No. Securities Lot Numbers As per 1. Equity shares of Re. 1/- each fully paid up SUDARSHAN EQ 254470600 1 Annexure I You are requested to mention the symbol and series in all future correspondence. All important information submitted by you pursuant to the various Regulations of SEBI (LODR), 2015 shall be broadcast through our nationwide network to the trading members. Please note that all reports, statements, intimations, documents, filings and/or any other information required to be filed by the listed entities under the respective SEBI Regulations/SEBI Circulars (as amended from time to time) shall be submitted by the Company only through ‘NEAPS’ – NSE Electronic Application Processing System (https://neaps.nseindia.com/NEWLISTINGCORP/), an online filing facility provided by the Exchange. The Exchange has hosted the contact details of the Exchange officials along with the profiles handled on NEAPS portal at Help>Contact Us The company shall ensure submission of financial results in accordance with Reg. 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 if migrated after the end of quarter but on/before due date for submission of said financial results. The National Stock Exchange of India (NSE) has launched the NEAPS mobile application. The new App offers listed entities a convenient way to track and monitor submission status, access the compliance calendar and stay updated on your stock performance and Exchange-related developments. The app can be downloaded from the App Store/ Play store and below is the QR code for the same. Continuation Sheet The login of the app is same as the existing NEAPS credentials and will be available for only those having neaps credentials. In case of any queries or suggestion, kindly drop an email on takeover@nse.co.in with the email subject as Suggestion for NSE NEAPS Mobile APP. If you require any further clarifications, we shall be glad to oblige. Yours faithfully, For National Stock Exchange of India Limited Snehal Mariappa Manager Continuation Sheet Annexure I Sudarshan Pharma Industries Limited No. of Equity Shares Distinctive Nos. Lock in upto Fully Paid-up From To 128226490 1 128226490 31-Dec-2027 9000000 128226491 137226490 20-Feb-2028 117244110 137226491 254470600 Free 254470600 Total